Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma
Standard
Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. / Kumar, Prashant; Nandi, Sayantani; Tan, Tuan Zea; Ler, Siok Ghee; Chia, Kee Seng; Lim, Wei-Yen; Bütow, Zentia; Vordos, Dimitrios; De la Taille, Alexandre; Al-Haddawi, Muthafar; Raida, Manfred; Beyer, Burkhard; Ricci, Estelle; Colombel, Marc; Chong, Tsung Wen; Chiong, Edmund; Soo, Ross; Park, Mi Kyoung; Ha, Hong Koo; Gunaratne, Jayantha; Thiery, Jean Paul.
in: ONCOTARGET, Jahrgang 6, Nr. 15, 30.05.2015, S. 13539-49.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma
AU - Kumar, Prashant
AU - Nandi, Sayantani
AU - Tan, Tuan Zea
AU - Ler, Siok Ghee
AU - Chia, Kee Seng
AU - Lim, Wei-Yen
AU - Bütow, Zentia
AU - Vordos, Dimitrios
AU - De la Taille, Alexandre
AU - Al-Haddawi, Muthafar
AU - Raida, Manfred
AU - Beyer, Burkhard
AU - Ricci, Estelle
AU - Colombel, Marc
AU - Chong, Tsung Wen
AU - Chiong, Edmund
AU - Soo, Ross
AU - Park, Mi Kyoung
AU - Ha, Hong Koo
AU - Gunaratne, Jayantha
AU - Thiery, Jean Paul
PY - 2015/5/30
Y1 - 2015/5/30
N2 - Transitional bladder carcinoma (BCa) is prevalent in developed countries, particularly among men. Given that these tumors frequently recur or progress, the early detection and subsequent monitoring of BCa at different stages is critical. Current BCa diagnostic biomarkers are not sufficiently sensitive for substituting or complementing invasive cystoscopy. Here, we sought to identify a robust set of urine biomarkers for BCa detection. Using a high-resolution, mass spectrometry-based, quantitative proteomics approach, we measured, compared and validated protein variations in 451 voided urine samples from healthy subjects, non-bladder cancer patients and patients with non-invasive and invasive BCa. We identified five robust biomarkers: Coronin-1A, Apolipoprotein A4, Semenogelin-2, Gamma synuclein and DJ-1/PARK7. In diagnosing Ta/T1 BCa, these biomarkers achieved an AUC of 0.92 and 0.98, respectively, using ELISA and western blot data (sensitivity, 79.2% and 93.9%; specificity, 100% and 96.7%, respectively). In diagnosing T2/T3 BCa, an AUC of 0.94 and 1.0 was attained (sensitivity, 86.4% and 100%; specificity, 100%) using the same methods. Thus, our multiplex biomarker panel offers unprecedented accuracy for the diagnosis of BCa patients and provides the prospect for a non-invasive way to detect bladder cancer.
AB - Transitional bladder carcinoma (BCa) is prevalent in developed countries, particularly among men. Given that these tumors frequently recur or progress, the early detection and subsequent monitoring of BCa at different stages is critical. Current BCa diagnostic biomarkers are not sufficiently sensitive for substituting or complementing invasive cystoscopy. Here, we sought to identify a robust set of urine biomarkers for BCa detection. Using a high-resolution, mass spectrometry-based, quantitative proteomics approach, we measured, compared and validated protein variations in 451 voided urine samples from healthy subjects, non-bladder cancer patients and patients with non-invasive and invasive BCa. We identified five robust biomarkers: Coronin-1A, Apolipoprotein A4, Semenogelin-2, Gamma synuclein and DJ-1/PARK7. In diagnosing Ta/T1 BCa, these biomarkers achieved an AUC of 0.92 and 0.98, respectively, using ELISA and western blot data (sensitivity, 79.2% and 93.9%; specificity, 100% and 96.7%, respectively). In diagnosing T2/T3 BCa, an AUC of 0.94 and 1.0 was attained (sensitivity, 86.4% and 100%; specificity, 100%) using the same methods. Thus, our multiplex biomarker panel offers unprecedented accuracy for the diagnosis of BCa patients and provides the prospect for a non-invasive way to detect bladder cancer.
M3 - SCORING: Journal article
C2 - 25915536
VL - 6
SP - 13539
EP - 13549
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 15
ER -